Why Bavarian Nordic (CPSE:BAVA) Could Be 36% Undervalued Following IMVANEX Child Approval
The latest move in Bavarian Nordic (CPSE:BAVA) stock interest comes after the European Commission approved an extension of the IMVANEX marketing authorization to include children aged 2 to under 12.
See our latest analysis for Bavarian Nordic.
Despite the positive regulatory news, Bavarian Nordic’s recent share price performance has been weak, with the 90 day share price return down 9.35% and the 1 year total shareholder return down 25.76%, while the 3 year total shareholder return remains positive at 8.89%.
If you are looking beyond Bavarian Nordic and want to see what else is happening in healthcare related technology, this could be a good moment to check out 129 healthcare AI stocks
Regulatory momentum for Bavarian Nordic now sits alongside a weak recent share price. The stock trades well below analyst targets and an internal value estimate, so does it make more sense to buy at this level, or to wait for a clearer entry point?
Most Popular Narrative: 35.5% Undervalued
The most followed narrative puts Bavarian Nordic’s fair value well above the last close of DKK176.4, which helps frame the recent price weakness.
The company's recent revenue surge and margin strength are heavily anchored in exceptional short-term demand for travel health and public preparedness vaccines, which may be unsustainable as contract wins and outbreak-based orders normalize. This could lead to a flattening or decline in revenues and/or increased volatility in future earnings as pandemic and epidemic fears subside.
Want to understand why this narrative still points to upside even with softer earnings expectations? The key is how revenue, margins and the future earnings multiple fit together.
Result: Fair Value of DKK273.33 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Bavarian Nordic’s reliance on a concentrated vaccine portfolio and its exposure to government pricing pressure could still challenge the underpriced narrative if conditions shift.
Find out about the key risks to this Bavarian Nordic narrative.
Next Steps
With sentiment split between opportunity and caution around Bavarian Nordic, this is a good moment to move quickly, review the full picture and shape your own view with the 4 key rewards and 1 important warning sign
Looking for more investment ideas beyond Bavarian Nordic?
If Bavarian Nordic has caught your attention, do not stop there. Use this moment to broaden your watchlist with focused ideas that match your investing style.
- Target potential upside in companies the market may be overlooking by scanning a curated group of 255 high quality undervalued stocks.
- Strengthen the income side of your portfolio by reviewing 439 dividend fortresses that aim to combine yield with resilience.
- Cut through noise and concentrate on financial strength by zeroing in on solid balance sheet and fundamentals stocks screener (422 results) that can better withstand shocks.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com